Form 4: Revolution Medicines CFO Jack Anders Reports Stock Option Grant and RSU Holdings

Chief Financial Officer of Revolution Medicines, Jack Anders, reports the acquisition of stock options and restricted stock units (RSUs) in the company.

Summary

• Jack Anders, the CFO of Revolution Medicines, filed a Form 4 detailing changes in beneficial ownership.
• On March 1, 2025, Anders acquired 20,400 shares of common stock and was granted options to purchase 71,400 shares.
• The stock options have an exercise price of $40.74 and expire on February 28, 2035.
• The options vest monthly over four years from March 1, 2025.
• Following these transactions, Anders beneficially owns 116,870 shares of common stock, including 65,276 restricted stock units, and options for 71,400 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, aligning management interests with shareholders through equity ownership.

Positives

• The grant of stock options and RSUs to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders and their alignment with shareholder interests.

Stakeholder Impact

• The reported transactions provide transparency to shareholders regarding the CFO's equity holdings in the company.
• The vesting schedule of the stock options incentivizes the CFO to remain with the company and contribute to its long-term success.

Key Dates